Peter Schmid, MD, PhD
Centre for Experimental Cancer Medicine (CECM), Barts Cancer Institute · Barts Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Schmid, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:44 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06954480 · Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerQueen Mary University of London · recruiting · Triple Negative Breast Cancer
- Ph3NCT03997123 · Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCAstraZeneca · active not recruiting · Triple Negative Breast Neoplasms · principal investigator
- Ph2NCT03841747 · Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerQueen Mary University of London · withdrawn · Breast Cancer
- Ph1/Ph2NCT03742102 · A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerAstraZeneca · active not recruiting · Triple Negative Breast Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.